GUTS (Fractyl Health) Change In Receivables : $0.02 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Fractyl Health Change In Receivables?

Fractyl Health's change in receivables for the quarter that ended in Sep. 2024 was $0.02 Mil. It means Fractyl Health's Accounts Receivable declined by $0.02 Mil from Jun. 2024 to Sep. 2024 .

Fractyl Health's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.02 Mil. It means Fractyl Health's Accounts Receivable increased by $0.02 Mil from Dec. 2022 to Dec. 2023 .

Fractyl Health's Accounts Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Fractyl Health's Days Sales Outstanding for the three months ended in Sep. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Fractyl Health's liquidation value for the three months ended in Sep. 2024 was $8.10 Mil.

Fractyl Health Change In Receivables Historical Data

The historical data trend for Fractyl Health's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fractyl Health Change In Receivables Chart

Fractyl Health Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.02

Fractyl Health Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial												0.03	-	0.01	-0.01	0.02

Fractyl Health Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

Fractyl Health (NAS:GUTS) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Fractyl Health's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.014	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Fractyl Health's accounts receivable are only considered to be worth 75% of book value:

Fractyl Health's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	84.664	-	76.602	+	0.75 * 0	+	0.5 * 0.073
=	8.10

Fractyl Health Change In Receivables Related Terms

Thank you for viewing the detailed overview of Fractyl Health's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Fractyl Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fractyl Health Inc (NAS:GUTS) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803

Website

https://www.fractyl.com

Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.